Cancer research sites demonstrated the utility of new resources designed to increase the diversity of participants in cancer clinical trials, although challenges remain, according to two studies published today in JCO Oncology Practice.
A phase II randomized clinical trial in people with stage IV non-small cell lung cancer (NSCLC) showed that adding a novel, engineered antibody to an immunotherapy resulted in better overall response rates (ORR) and progression-free survival (PFS) compared to treatment with the immunotherapy drug alone.
Prior authorization is harming individuals with cancer according to new survey results from the Association for Clinical Oncology (ASCO). The survey found that prior authorization delays necessary care, worsens cancer care outcomes, and diverts clinicians from caring for their patients.
The American Society of Clinical Oncology, Inc. (ASCO®) and the European Cancer Organisation (ECO) are pleased to announce a new collaboration, formalized with a recently signed memorandum of understanding, that will advance their shared aims on cancer control.
In the largest study to date of chimeric antigen receptor (CAR) T-cell therapy for relapsed and refractory childhood B-cell acute lymphoblastic leukemia (B-ALL), clinicians in China were able to rapidly produce dual CD19/CD22 targeted T-cells, resulting in treatments that led to undetectable disease in 99% of 194 patients with treatment-resistant or high-risk-of-relapse leukemia, according to a study published today in the Journal of Clinical Oncology.
The American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) today released a joint policy statement outlining the latest research on the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) and recommendations for regulating these products to protect public health. The statement was published in the AACR’s journal Clinical Cancer Research and ASCO’s Journal of Clinical Oncology.
In conjunction with the World Cancer Congress, the American Society of Clinical Oncology, Inc. (ASCO®) is publishing a special series of its online publication JCO Global Oncology focused on innovative, evidence-based models for cancer professionals and patients to improve access to quality cancer care particularly in low- and middle-income countries (LMICs). During Congress sessions, leaders from ASCO will explore integrating palliative care into standard oncology practice; increasing cancer research and clinical trials in Africa; ensuring a supply of essential medicine for all patients regardless of resource setting; and using lessons learned from the COVID-19 pandemic to boost cancer control.https://ascopubs.org/doi/full/10.1200/GO.22.00168
Alexandria, VA. – Building on its longstanding commitment to health equity, the American Society of Clinical Oncology (ASCO) is launching a multi-year pilot program to increase access to high-quality, equitable cancer care in rural Montana.
State-run Medicaid insurance, expanded in 2014 as part of the Affordable Care Act, has resulted in decreased metastatic cancer incidence rates as well as decreased overall cancer mortality rates and averted over one thousand deaths due to cancer per year. About 12% of the improvements in cancer mortality were due to decreases in metastatic diagnoses, according to a study to be presented as part of the 2022 ASCO Quality Care Symposium.
A cancer navigation program can reduce overall costs when deployed in collaboration with a statewide Medicare Advantage health plan across a wide range of practice types, according to findings to be presented as part of the 2022 ASCO Quality Care Symposium.
Substituting biosimilars, generics and clinically appropriate lower cost drugs for established, costlier drugs was shown to be an effective way to reduce the total cost of care, by 5% or so, while maintaining the quality of care for patients with cancer. Even small shifts towards lower cost drugs resulted in significant reductions in the total cost of care, according to a study to be presented as part of the 2022 ASCO Quality Care Symposium.
“President John F. Kennedy’s historic speech that inspired our nation and an entire generation of Americans to achieve manned space exploration underscored the courage and commitment it would take to accomplish this then-audacious goal: ‘We choose to go to the moon in this decade and do the other things, not because they are easy, but because they are hard.’
Studies evaluating interventions to reduce the total cost of cancer care and a new analysis of changes in cancer incidence and mortality rates after Medicaid expansion under the Affordable Care Act will be highlighted in the 2022 American Society of Clinical Oncology (ASCO) Quality Care Symposium’s official Press Program. Studies featured in the Press Program are among the nearly 500 abstracts that will be presented at the Symposium.
Testing for pathogenic germline variants (PGVs) – genetic changes present from the time of conception, those that have been inherited – can help identify patients at risk for hereditary cancers. The role of PGVs in lung cancer has been underrecognized, largely due to the fact that it is mostly assumed to be caused by environmental factors such as cigarette smoking. A new study of patients with lung cancer, however, found that nearly 15% had PGVs, which means they and their family members are at an increased risk for other types of cancers. The results of the study will be presented during the ASCO Plenary Series session taking place August 16, 2022, at 3:00 PM (ET).
The American Society of Clinical Oncology (ASCO) applauds President Biden for his decision to appoint ASCO-Past President Monica M. Bertagnolli, MD, FACS, FASCO, as the new Director of the National Cancer Institute (NCI). An accomplished cancer surgeon and researcher with deep expertise in community-based cancer research, Dr. Bertagnolli has the knowledge, passion, and skillset to successfully lead the nation’s top federal cancer research agency and the wider U.S. cancer research enterprise. We enthusiastically endorse her selection, recognizing Dr. Bertagnolli’s distinguished leadership and experience in advancing evidence-based cancer care and research.